Both Secukimuab and Ixekizumab target IL-17A [190], while Brodalumab binds with high affinity to the IL17RA subunit, simultaneously inhibiting IL-17A, IL-17F, IL-17C, and IL-17E and providing a > 95% improvement in upregulated psoriasis genes after 12 weeks of treatment [191]. The gene discussed is IL17F; the disease is psoriasis.